Trials
MRD trials
The curated index is a sourced list of studies. Accruing is the live ClinicalTrials.gov set of studies that are recruiting or not yet recruiting. DYNAMIC-III is not in the curated index because it is registered in Australia and New Zealand, not with an NCT id.
Recruiting and not-yet-recruiting studies that use ctDNA, cfDNA, or MRD in eligibility, a treatment decision, or a primary or secondary endpoint, plus observational studies focused on that testing. 1123 studies from 2267 registry records. Hematologic trials that list MRD only as a secondary endpoint are listed separately. Last synced Nov 18, 2026, 2:04 PM EST.
This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.
Pfizer · 319 locations · Updated 2026-10-14
ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer
Karolinska Institutet · 32 locations · Updated 2025-04-09
Study of Ifinatamab Deruxtecan in De Novo or Treatment-Emergent Neuroendocrine Prostate Cancer
Rahul Aggarwal · 1 locations · Updated 2026-11-09
Phase II Non-Randomized Study Evaluating POSLUMA-PSMA PET Response After Oligo- Metastatic/Progressive-directed Treatment With Radiotherapy (PROMPT-R)
City of Hope Medical Center · 1 locations · Updated 2026-10-29
[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
Washington University School of Medicine · 3 locations · Updated 2026-10-21
Measuring Circulating Tumor Deoxyribonucleic Acid Tumor Fraction to Guide Early 177Lu-PSMA-617 Treatment Discontinuation in Patients With Metastatic Castration-Resistant Prostate Cancer, DYNAMO Trial
University of Washington · 1 locations · Updated 2026-10-19
Clinical Trial to Test Efficacy of Targeting Hypoxia Combined With ARSI After First-line ARSI Therapy for Castrate Resistant Prostate Cancer
University Health Network, Toronto · 1 locations · Updated 2026-09-24
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
Institute of Cancer Research, United Kingdom · 4 locations · Updated 2026-09-08
Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation
University of California, Irvine · 1 locations · Updated 2026-05-06
Green Tea and Quercetin in Combination With Docetaxel Chemotherapy in Castration-resistant Prostate Cancer Patients
Charles Drew University of Medicine and Science · 1 locations · Updated 2026-04-15
Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 2 locations · Updated 2024-03-12
Neoadjuvant PSMA-RLT in Oligometastatic PCa
Medical University of Vienna · 1 locations · Updated 2024-02-15
PSMA-RLT in Biochemically Recurrent PCa
Medical University of Vienna · 1 locations · Updated 2024-02-13
Collection of Blood From Patients With Prostate Cancer
National Cancer Institute (NCI) · 1 locations · Updated 2026-11-12
Circulating Tumor DNA in High Risk Localized Prostate Cancer
University of Pittsburgh · 1 locations · Updated 2026-11-09
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
AstraZeneca · 28 locations · Updated 2026-10-22
Impact of DNA Repair Pathway Alterations on Sensitivity to Radium-223 in Bone Metastatic Castration-resistant Prostate Cancer
University of Washington · 4 locations · Updated 2026-10-22
Prospective Prostate Cancer Infrastructure
Radboud University Medical Center · 1 locations · Updated 2026-09-10
COMPASS Study for Metastatic Castration-resistant Prostate Cancer
Duke University · 4 locations · Updated 2026-08-27
Feasibility Study of Urinary cfDNA Analysis as a Non-invasive Monitoring Tool in Patients With Prostate or Bladder Cancer
Institut Cancerologie de l'Ouest · Locations not reported · Updated 2026-03-16
Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer
British Columbia Cancer Agency · 1 locations · Updated 2026-02-02
Detection of Minimal Residual Disease Post-prostatectomy
Radboud University Medical Center · 1 locations · Updated 2026-01-12
Liquid Biopsy Under PSMA Radioligand Therapy
Wuerzburg University Hospital · 3 locations · Updated 2025-08-12
Feasibility and Impact of Liquid Biopsy Genomic Profiling on Treatment Patients With Metastatic Prostate Cancer in Spain (SOLTI-2102)
SOLTI Breast Cancer Research Group · 1 locations · Updated 2025-08-06
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Istituto Clinico Humanitas · 3 locations · Updated 2025-07-30
The Radium-select Study
The Netherlands Cancer Institute · 5 locations · Updated 2025-07-08
PRostate Cancer Plasma Integrative Multi-modal Evaluation
Santa Chiara Hospital · 4 locations · Updated 2025-05-20
CART-PSMA Cells for Advanced Prostate Cancer
Nova Therapeutics LLC · 1 locations · Updated 2024-11-15
Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
Yonsei University · 1 locations · Updated 2019-12-13
Status can change after this sync. The curated list is the other view on this page. Evidence holds the published results.